Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...

Novo Nordisk has been drafting a number of nonexclusive partnerships for its as-yet unlaunched pen offering. When it first announced the product, it already had partnerships in place with with Dexcom, ...